Antianginal drug withdrawal syndrome. Clinical significance and precautions

Antianginal drug withdrawal syndrome. Clinical significance and precautions

Every practicing physician can experience withdrawal syndrome. It is characteristic of a wide variety of drugs - sleeping pills, tranquilizers, corticosteroids, antiepileptic drugs, etc. Drugs used in cardiology are no exception. The withdrawal syndrome of clonidine, beta-blockers and a number of other drugs is well known.

• Manifestations of antianginal drug withdrawal syndrome

In patients with coronary artery disease (CHD) with stable angina pectoris, discontinuation of an antianginal drug can cause a significant increase in angina attacks and a decrease in exercise tolerance. In rare cases, acute myocardial infarction may develop. Since almost all antianginal drugs reduce blood pressure to one degree or another, stopping their use often causes an increase, sometimes quite significant. Recently, evidence has emerged that in some cases, withdrawal of an antianginal drug can cause the appearance of so-called asymptomatic myocardial ischemia [1].

Withdrawal syndrome is most typical for drugs that are quickly eliminated from the body. The faster the drug is removed from the body, the more pronounced the withdrawal syndrome may be.

One should not think that withdrawal syndrome develops only after complete cessation of taking the drug (Table 1). It has been established that withdrawal syndrome can also occur during treatment, in the intervals between the effects of successive doses of the drug. This is possible, firstly, when the interval between taking two doses of the drug is sufficiently long. For example, it is possible that withdrawal syndrome may develop in the morning, before taking the next dose of the drug, when the effect of the previous dose has expired. This type of withdrawal syndrome is called the “zero-hour phenomenon” (in English - zero-hour phenomenon) [2].

Table 1. Patterns of withdrawal syndrome

Secondly, as mentioned above, during treatment, withdrawal syndrome may occur if the drug is very quickly eliminated from the body. In such cases, withdrawal syndrome is often called the rebound effect or the phenomenon of negative aftereffects. This is possible, in particular, when using some short-acting dosage forms (for example, short-acting nifedipine) or if a method of introducing the drug into the body is chosen that allows the drug to be abruptly stopped (for example, when the intravenous administration of the drug is abruptly stopped or when it is removed from the skin transdermal dosage form of the drug).

All of the above indicates that withdrawal syndrome, firstly, can significantly affect the safety of therapy with antianginal drugs (in some cases, due to the development of withdrawal syndrome, therapy can even have a paradoxical effect). Secondly, the occurrence of withdrawal syndrome is usually quite predictable, and knowledge of the clinical pharmacology of the drugs used can help prevent its occurrence.

Below is information about the possibility of withdrawal syndrome from various groups of antianginal drugs.

• Nitrates

Nitrates were the first antianginal drugs for which a withdrawal syndrome was described. As early as 1898, GC Laws reported a deterioration in the health of workers engaged in the production of gunpowder on weekends [3]. Subsequently, quite a lot of works appeared containing documented information about cases of sudden death of workers involved in the production of dynamite, which occurred on weekends when contact with nitrates ceased [4, 5]. Nitrate withdrawal syndrome as such was first described in the mid-twentieth century, when it was shown that some workers involved in the production of dynamite experienced typical attacks of angina on weekends, not associated with physical activity. Several cases of myocardial infarction and even sudden death have been reported in workers employed in such industries during the period of cessation of nitrate exposure. A thorough study with coronary angiography did not reveal atherosclerotic changes in the coronary arteries of persons who had myocardial infarction during the period of cessation of contact with nitrates [6]. In addition, it was noted that in workers who experienced chest pain on weekends, angina attacks completely disappeared after prolonged isolation from nitrate exposure. The condition that arose during the period of abrupt cessation of the action of nitrates began to be called the rebound phenomenon [7]. For a long time, it was believed that the nitrate withdrawal syndrome described above occurs only when exposed to large doses at work, but is not typical for the clinical use of these drugs. However, special studies have shown that nitrate withdrawal syndrome also occurs in clinical practice. In table Table 2 presents the main symptoms associated with the manifestation of isosorbide dinitrate withdrawal syndrome in patients with stable angina pectoris.

Table 2. Clinical manifestations of isosorbide dinitrate and nifedipine withdrawal syndrome

(according to a randomized crossover study in 18 patients with stable angina pectoris) [10]

Interest in nitrate withdrawal syndrome increased significantly in the late 1980s, when various regimens of intermittent administration of these drugs began to be widely recommended to prevent the development of addiction to them. Intermittent administration of nitrates suggests that there should be a period during the day when the body is free from the effects of nitrate (nitrate-free period). During this period, sensitivity to nitrates, which decreased as a result of their previous use, has time to recover [4].

It turned out, however, that with intermittent administration of nitrates there is a risk of developing withdrawal syndrome. Thus, it was shown that after removing transdermal nitroglycerin stickers from the skin at night, approximately 8% of patients experience attacks of angina at rest that were absent previously [8]. One of the manifestations of nitrate withdrawal syndrome during their intermittent administration may also be the appearance of episodes of asymptomatic myocardial ischemia [1]. All this indicates that intermittent administration of nitrates, along with undoubted advantages, is fraught with very real danger.

Studies have shown, however, that the clinical significance of nitrate withdrawal syndrome when administered intermittently is directly dependent on the severity of the patients' condition: in patients with a relatively mild and stable course of the disease, short-term withdrawal of the drug, as a rule, does not cause negative consequences and is completely safe. In patients with more severe coronary heart disease, in the presence of signs of hemodynamic impairment, the consequences of withdrawal syndrome can be much more severe [9]. Therefore, intermittent administration of nitrates is quite acceptable in patients with a stable and relatively mild course of coronary artery disease (this includes patients with stable angina of functional class 1-3). In patients with more severe coronary artery disease (stable angina of the 4th functional class) or signs of instability (unstable angina, acute myocardial infarction), intermittent administration of nitrates should be avoided [10].

• Beta blockers

Clinicians encountered the possibility of developing beta-blocker withdrawal syndrome almost immediately as soon as these drugs began to be used in clinical practice. It has been shown that sudden withdrawal of propranolol can cause a sharp increase in angina attacks, severe arrhythmias, acute myocardial infarction, and even sudden death. Subsequently, it turned out that such severe manifestations of propranolol withdrawal syndrome are observed in no more than 5% of patients; much more often, doctors encounter such a manifestation of propranolol withdrawal syndrome as the occurrence of tachycardia [11].

It also turned out that different beta-blockers have the ability to cause withdrawal symptoms to varying degrees. Thus, the severity of the withdrawal syndrome of cardioselective beta-blockers, in particular atenolol, turned out to be much less than the severity of the withdrawal syndrome of propranolol [12]. Obviously, it is possible to prevent the occurrence of beta-blocker withdrawal syndrome only through their gradual withdrawal. Discontinuation regimens for these drugs, however, may vary significantly. Thus, a number of authors recommend discontinuing propranolol by gradually reducing the dose in steps over 6-9 days. Other authors consider another regimen safer: the dose of propranolol is immediately reduced to a small dose (30 mg per day), then the drug is taken at this dosage for two weeks, and then completely discontinued [13].

• Calcium antagonists

Until recently, the possibility of withdrawal syndrome from this group of drugs caused controversy among researchers [14]. It has now become obvious that these drugs differ quite significantly in their pharmacological properties, and accordingly, they are capable of causing withdrawal syndrome to varying degrees.

Verapamil. Apparently, taking this drug is associated with the least risk of withdrawal syndrome of all antianginal drugs. This is primarily due to the ability of verapamil to accumulate in the body with regular use. Accordingly, when you stop taking verapamil, the drug is eliminated from the body for quite a long time and its effect persists for several days after taking the last dose of the drug.

To date, there is not a single study that has clearly proven the existence of verapamil withdrawal syndrome. As a result of comparing the effect of discontinuation of propranolol and verapamil, carried out in 20 patients with stable angina pectoris, it was possible to prove that after stopping taking verapamil, there was a gradual return of the frequency of angina attacks to the initial level, and after stopping taking propranolol, on the contrary, a sharp increase in angina attacks and a significant decrease exercise tolerance [15]. This gives grounds to assert that if it is necessary to stop taking verapamil, it can be discontinued immediately, without gradually reducing the dose.

When verapamil is taken regularly, even in the form of regular tablets, its effect can be considered fairly uniform, so this drug never causes the rebound phenomenon.

Diltiazem. To date, practically no work has been carried out to study the possibility of developing diltiazem withdrawal syndrome in patients with stable angina.

We recently conducted a special study, the purpose of which was, in particular, to establish whether withdrawal symptoms occur after abruptly stopping regular (four times a day) use of this drug for four weeks. The comparison drug was nifedipine, which was prescribed for the same period and then discontinued. The study was conducted using a double-blind, randomized, parallel design.

It was demonstrated that discontinuation of diltiazem was associated only with the fact that the number and duration of myocardial ischemic episodes (as measured by 24-hour ECG monitoring) returned to baseline levels. Exercise tolerance, as measured by the treadmill test, simply returned to pre-treatment levels when diltiazem was discontinued (see figure). In contrast, on the first day of discontinuation of nifedipine, there was a noticeable increase (compared to the control period) in the number of episodes of myocardial ischemia, while at the same time there was a decrease in exercise tolerance below the level recorded before the start of treatment.

Thus, abrupt cessation of diltiazem did not cause withdrawal symptoms; abrupt cessation of taking nifedipine, on the contrary, led to an objective deterioration in the patients’ condition, which can be considered a manifestation of the withdrawal syndrome of this drug.

Nifedipine. It was reported above that sudden cessation of regular use of nifedipine [10] may cause withdrawal symptoms. However, and this seems more important, it has been found that nifedipine withdrawal syndrome may occur during therapy with this drug if short-acting dosage forms are used. We have proven that in the morning, before taking the next dose of nifedipine, exercise tolerance was lower than in the control period (this condition is called the zero-hour phenomenon). At the same time, in a number of patients, the appearance of attacks of angina pectoris at rest, which were absent before treatment, was noted [16].

As in the case of nitrates, the consequences of nifedipine withdrawal syndrome are directly dependent on the severity of the patient's condition. If in patients with a relatively mild course of the disease, withdrawal syndrome, even if it manifests itself with obvious symptoms, may not have any serious consequences, then in patients with an unstable course of the disease, the consequences of this syndrome can be much more severe. There is every reason to believe that a number of severe complications, including such as the development of acute myocardial infarction and sudden death, recorded in some studies in which nifedipine was prescribed for unstable angina and acute myocardial infarction in a short-acting dosage form, were explained precisely by the development short-term withdrawal syndrome of nifedipine (rebound phenomenon) due to its use [17, 18].

It must be emphasized that some drugs, in particular beta-blockers, can prevent the rebound phenomenon. Thus, it has been proven that if the use of short-acting nifedipine as monotherapy for unstable angina is associated with an increased risk of complications, then the use of the same drug in combination with beta-blockers is safe and can even improve the prognosis of the disease [17]. It should be noted that the rebound phenomenon is most characteristic of nifedipine, produced in the form of so-called rapidly disintegrating capsules (in Russia it is known as adalat), which contribute to a rapid increase and an equally rapid decrease in the concentration of the drug in the blood. When nifedipine is prescribed in the form of regular tablets (in Russia they are known under the names Corinfar, Cordafen, etc.), the severity of rebound syndrome may be less.

Recently, special dosage forms of nifedipine with prolonged action have been created (for example, nifedipine-SR, known in Russia as adalat-SL, or nifedipine-GITS, known in Russia as osmo-adalat), helping to maintain a more or less constant concentration of the drug in the blood. These dosage forms, according to currently available data, do not cause the rebound phenomenon and can be used in patients with unstable IHD.

The presented data indicate that withdrawal syndrome in its various forms can significantly affect the effectiveness and safety of therapy for patients with coronary artery disease. Situations are quite real when neglecting the risk of developing withdrawal syndrome leads to a result opposite to the desired one (as happened, for example, when trying to prescribe short-acting nifedipine as monotherapy to patients with unstable angina). On the contrary, competent prescription of the drug, taking into account its possible side and undesirable effects, as well as the characteristics of the course of the disease in a particular patient, can significantly improve the outcome of treatment.

References
1. Martsevich S. Yu., Koutishenko NP, Metelitsa VI Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris. Heart 1996; 75: 447-450. 2. Thadani U. Nitrate tolerance, rebound and their clinical significance in stable angina pectoris, unstable angina, and heart failure // Cardiovasc. Drugs Ther. 1996; 10: 735-742. 3. Laws GC The effects of nitroglycerin upon those who manufacture it. JAMA 1898; 31: 793. 4. Carmichael P., Lieben J. Sudden death in explosive workers // Arch. Environ. Health. 1963; 7: 50. 5. Lund RP, Haggendahl J., Johnsson G. Withdrawal symptoms in workers exposed to nitroglycerine // Br. J. Ind. Med. 1968; 25: 136. 6. Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM, Coolidge G. Nonatheromatous ischemic heart disease following withdrawal from industrial nitroglycerin exposure. Circulation 1972; 46: 666-678. 7. Abrams J. Nitrate tolerance and dependence // Am. Heart J. 1980; 99: 113-123. 8. DeMots H, Glasser SP, Transdermal-Nitro Trial Study Group. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina // J. Amer. Coll. Cardiol. 1989; 13: 786-793. 9. Martsevich S.Y., Koutishenko N., Metelitsa VI Withdrawal effects of antianginal therapy: comparison of isosorbide dinitrate and nifedipine // Int. J. Cardiol. 1998; 64: 137-144. 10. Martsevich S. Yu. Refractoriness to antianginal drugs and the development of tolerance to them in patients with coronary heart disease. Methods of detection, clinical significance, possibility of prevention. Author's abstract. dis. doc. honey. Sci. M., 1994: 44 p. 11. Shand DG, Wood AJJ Propranolol withdrawal syndrome - why? Circulation 1978; 58: 202-203. 12. Walker PR, Marshall AJ, Farr S., Bauminger B., Walters G., Barritt DW Abrupt withdrawal of atenolol in patients with severe angina // Br. Heart J 1985; 53: 276-282. 13. Rangno RE, Nattel S., Lutterodt A. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule // Am. J. Cardiol. 1982; 49: 828-833. 14. Lambert CR, Pepine CJ Is there a calcium-antagonist withdrawal syndrome? //Pract. Cardiol. 1987; 13: 190-195. 15. Frishman WH, Klein N., Strom J., Cohen MN, Shamoon H., Willens H., Klein P., Roth S., Iorio L., LeJemtel T., Pollack S., Sonnenblick H. Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris. Am. J. Cardiol. 1982; 50: 1191-1195. 16. Martsevich S. Yu., Kutishenko N. P., Alimova E. V., Slastnikova I. D., Metelitsa V. I. Calcium antagonists diltiazem and nifedipine: comparison of effectiveness with single and long-term use in patients with stable angina pectoris. Ter. arch. 1998; 8:21-25. 17. The Holland Interuniversity Nifedipine/metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double-blind, placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. // Br. Heart J 1986; 56: 400-413. 18. Goulbourt U., Behar S., Reicher-Reiss H. et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention of Reinfarction Israel Nifedipine Trial 2 Study. //Arch. Intern. Med. 1993; 153: 345-353.

Concor®

Termination of therapy and “withdrawal syndrome”

You should not abruptly interrupt treatment with bisoprolol or change the recommended dose without first consulting your doctor, as this may lead to a temporary deterioration in heart function.

Treatment should not be interrupted suddenly, especially in patients with coronary artery disease (worsening attacks of angina pectoris, the development of myocardial infarction and the occurrence of ventricular arrhythmias in patients with coronary artery disease have been noted when taking beta-blockers suddenly). If discontinuation of treatment is necessary, the dose of bisoprolol should be reduced gradually. In case of significant worsening of angina or development of acute coronary syndrome, bisoprolol should be temporarily resumed.

Diseases for which the drug should be used with caution

Bisoprolol should be used with caution in the following cases:

- severe forms of COPD and non-severe forms of bronchial asthma;

- diabetes mellitus with significant fluctuations in blood glucose concentrations: bisoprolol may mask symptoms of hypoglycemia (a marked decrease in blood glucose concentrations), such as tachycardia, palpitations or increased sweating;

- strict diet;

— carrying out desensitizing therapy;

— atrioventricular block of the first degree;

- vasospastic angina (Prinzmetal's angina); cases of coronary spasm have been observed. Despite its high beta1 selectivity, angina attacks cannot be completely excluded when taking bisoprolol in patients with Prinzmetal's angina. You should take the drug with extreme caution;

- mild to moderate peripheral arterial circulation disorders (increased symptoms may occur at the beginning of therapy);

- psoriasis (including history).

Diseases of the cardiovascular system

Beta blockers should not be used in decompensated chronic heart failure until the patient's condition has stabilized.

At the initial stages of using bisoprolol, patients need constant monitoring.

Beta blockers may cause bradycardia. If the resting heart rate decreases to less than 50-55 beats/min, the dose should be reduced or discontinued taking bisoprolol.

Like other beta blockers, bisoprolol may cause a prolongation of the PQ interval on the ECG. Bisoprolol should be used with caution in patients with first degree atrioventricular block.

Non-selective beta-blockers may increase the frequency and duration of anginal attacks in patients with vasospastic angina (Prinzmetal's angina) due to alpha-receptor-mediated coronary artery vasoconstriction.

Cardioselective beta-blockers (including bisoprolol) should be used with caution in vasospastic angina.

To date, there is insufficient data regarding the use of bisoprolol in patients with CHF in combination with type 1 diabetes mellitus, severe renal and/or liver dysfunction, restrictive cardiomyopathy, congenital heart defects or heart valve disease with severe hemodynamic disturbances. Also, sufficient data have not yet been obtained regarding patients with CHF with myocardial infarction within the last 3 months.

Respiratory system

Despite the fact that selective beta-blockers have a lesser effect on the function of the respiratory system than non-selective beta-blockers, patients with chronic obstructive pulmonary disease COPD and mild forms of bronchial asthma should be prescribed bisoprolol with extreme caution and only if possible the benefits of its use outweigh the potential risks.

For bronchial asthma or COPD, simultaneous use of bronchodilators is indicated. In patients with bronchial asthma, there may be an increase in airway resistance, which requires a higher dose of beta2-agonists.

In patients with COPD, bisoprolol prescribed in combination therapy for the treatment of heart failure should be started at the lowest possible dose, and patients should be carefully monitored for the appearance of new symptoms (eg, shortness of breath, exercise intolerance, cough).

Major surgery and general anesthesia

If surgical interventions are necessary, the anesthesiologist should be warned that the patient is taking beta-blockers (risk of drug interactions with the development of severe bradyarrhythmias, reduction of reflex tachycardia and arterial hypotension). It is recommended not to stop taking bisoprolol in the perioperative period unless clearly necessary (since beta-adrenergic receptor blockade reduces the risk of arrhythmias and myocardial ischemia during induction of anesthesia and tracheal intubation).

If it is necessary to interrupt treatment with bisoprolol before surgery, the drug should be discontinued at least 48 hours before surgery.

Pheochromocytoma

In patients with pheochromocytoma, bisoprolol can only be prescribed while using alpha-blockers.

Thyrotoxicosis

With hyperthyroidism, beta-blockers (including bisoprolol) can mask tachycardia and reduce the severity of symptoms of thyrotoxicosis. Abrupt withdrawal of the drug can cause exacerbation of symptoms of the disease and the development of thyrotoxic crisis.

Hypersensitivity reactions

Beta blockers, including bisoprolol, may increase sensitivity to allergens and the severity of anaphylactic/hypersensitivity reactions due to decreased adrenergic compensatory regulation by beta blockers. The use of usual therapeutic doses of epinephrine (adrenaline) while taking beta-blockers does not always lead to achieving the desired clinical effect.

Caution should be exercised when prescribing bisoprolol to patients with a history of severe hypersensitivity reactions or undergoing desensitization.

Psoriasis

When deciding on the use of bisoprolol in patients with psoriasis, the expected benefits of the drug should be carefully weighed against the possible risk of exacerbation of psoriasis.

Contact lenses

Patients who use contact lenses should take into account that the use of beta-blockers may reduce the production of tear fluid.